These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 26134233)

  • 1. Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib.
    Toyokawa G; Inamasu E; Shimamatsu S; Yoshida T; Nosaki K; Hirai F; Yamaguchi M; Seto T; Takenoyama M; Ichinose Y
    J Thorac Oncol; 2015 Jul; 10(7):e55-7. PubMed ID: 26134233
    [No Abstract]   [Full Text] [Related]  

  • 2. A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer.
    Biya J; Caramella C; Lindsay CR; Planchard D; Besse B
    J Thorac Oncol; 2015 Jun; 10(6):e44-5. PubMed ID: 26001149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer.
    Kaczmar J; Mehra R
    Ther Adv Respir Dis; 2015 Oct; 9(5):236-41. PubMed ID: 26229087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.
    Kodityal S; Elvin JA; Squillace R; Agarwal N; Miller VA; Ali SM; Klempner SJ; Ou SH
    Lung Cancer; 2016 Feb; 92():19-21. PubMed ID: 26775591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
    Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
    Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
    Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
    Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
    Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
    Califano R; Greystoke A; Lal R; Thompson J; Popat S
    Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer.
    Facchinetti F; Caramella C; Auger N; Planchard D; Adam J; Lacroix L; Remon J; Massard C; Soria JC; Friboulet L; Besse B
    Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27197808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.
    Landi L; Cappuzzo F
    Expert Rev Clin Pharmacol; 2016; 9(2):203-14. PubMed ID: 26582431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Efficacy of Alectinib in Patients with
    Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
    Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC.
    Gelsomino F; Ambrosini V; Melotti B; Sperandi F; Ardizzoni A
    J Thorac Oncol; 2016 Aug; 11(8):e99-e101. PubMed ID: 27079186
    [No Abstract]   [Full Text] [Related]  

  • 13. Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.
    Vansteenkiste JF
    Future Oncol; 2014 Oct; 10(12):1925-39. PubMed ID: 24856155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceritinib Outperforms Chemo as Second-Line Treatment.
    Cancer Discov; 2016 Dec; 6(12):OF5. PubMed ID: 27780805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceritinib gains FDA approval for lung cancer.
    Cancer Discov; 2014 Jul; 4(7):753-4. PubMed ID: 25002599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LDK378 compassionate use for treating carcinomatous meningitis in an ALK translocated non-small-cell lung cancer.
    Arrondeau J; Ammari S; Besse B; Soria JC
    J Thorac Oncol; 2014 Aug; 9(8):e62-3. PubMed ID: 25157781
    [No Abstract]   [Full Text] [Related]  

  • 17. 18F-FDG PET/CT Evaluation of Ceritinib Therapy in Metastatic ALK-Positive Non-small Cell Lung Cancer.
    Dejust S; Morland D; Fabre G; Prevost A; Papathanassiou D
    Clin Nucl Med; 2016 Nov; 41(11):879-880. PubMed ID: 27607176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the battle against lung tumour resistance.
    Furlow B
    Lancet Respir Med; 2014 May; 2(5):353. PubMed ID: 24963524
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
    Lau YY; Gu W; Lin T; Viraswami-Appanna K; Cai C; Scott JW; Shi M
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1119-1128. PubMed ID: 28424965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second- and third-generation ALK inhibitors for non-small cell lung cancer.
    Wu J; Savooji J; Liu D
    J Hematol Oncol; 2016 Mar; 9():19. PubMed ID: 26951079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.